Rituxirnab (Anti-CD20 Monoclonal Antibody) Administration in a Young Patient with Resistant B-Prolymphocytic Leukemia

Following the administration of the human anti-CD20 monoclonal antibody IDEC-C2B8 (rituxirnab), a 31-yearold woman with B-prolymphocytic leukemia, who had been resistant to CHOP, fludarabine, pentostatin and 2CdA, achieved complete remission. Rituxirnab was administered intravenously once a week for 4 weeks. The patient only had mild but tolerable side effects during the first cycle of therapy. She remains in complete remission 8 months following the discontinuation of treatment.